Denali Therapeutics Inc. (9)
Browse by Contract Category
Contracts
-
Common Stock Purchase Agreement between the Registrant and Biogen Inc., dated August 5, 2020
(Filed With SEC on November 5, 2020)
-
Provisional LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated August 5, 2020
(Filed With SEC on November 5, 2020)
-
Definitive R
(Filed With SEC on November 5, 2020)
-
Form of Amended and Restated Change in Control and Severance Plan
(Filed With SEC on November 5, 2020)
-
Standstill and Stock Restriction Agreement between the Registrant and Biogen Inc., dated September 22, 2020
(Filed With SEC on November 5, 2020)
-
Definitive LRRK2 Collaboration and License Agreement
(Filed With SEC on November 5, 2020)
-
Amended and Restated Outside Director Compensation Policy
(Filed With SEC on May 7, 2020)
-
Description of the registrants common stock
(Filed With SEC on February 27, 2020)
-
Underwriting Agreement, dated as of January 28, 2020, among Denali Therapeutics Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Jefferies LLC, as representatives...
(Filed With SEC on January 29, 2020)